We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended the use of subcutaneous injection of Takeda’s Takhzyro (lanadelumab) to prevent recurrent attacks ...
Santhera Pharmaceuticals has licensed a drug called Raxone, indicated for the treatment of Leber’s hereditary optic neuropathy (LHON), to Chiesi Farmaceutici (Chiesi Group).
New study found that both genetic and epigenetic differences between the maternal and paternal allele contributed to the observed tissue-specific activity patterns, uncovering the first complete allelome.